Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 18 2022 - 8:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of July 2022
Commission
File Number 001-37381
MEDIGUS LTD.
(Translation of registrant’s name into English)
3
HaNechoshet Street, building B, 6971068, Tel Aviv, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
EXPLANATORY
NOTE
On
July 18, 2022, Medigus Ltd. issued a press release titled: “Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal
Administration of Cutting - Edge Therapy for Spinal Cord Injuries.” A copy of this press release is furnished herewith as Exhibit
99.1.
EXHIBIT
INDEX
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
MEDIGUS
LTD. |
|
|
|
Date:
July 18, 2022 |
By: |
/s/
Tali Dinar |
|
|
Tali
Dinar |
|
|
Chief
Financial Officer |
2
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Sep 2023 to Sep 2024